In a meta-analysis 6 of eight trials with 60080 patients (ELIXA, LEADER, SUSTAIN-6, EXSCEL, Harmony Outcomes, REWIND, PIONEER 6, and AMPLITUDE-O) , treatment with a GLP-1 receptor agonist led to a 14% relative risk reduction in three-point MACE (HR 086 [95% CI 080093]
Insurance coverage and support: Many of Ros GLP-1s are available through insurance, and Ro offers members support navigating coverage, while Hers options are paid for out-of-pocket
This is especially beneficial for individuals with diabetes or those at risk of developing the condition
A unique and catchy name can set you apart
If you have had a cardiac event and you are also overweight, this is often a better coverage path than the Bridge because the drug cost counts toward your annual out-of-pocket cap
Your weight loss starts with a comprehensive medical evaluation